mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL
Sign Up to like & getrecommendations! Published in 2018 at "Oncotarget"
DOI: 10.18632/oncotarget.24020
Abstract: High-risk subtypes of B-cell acute lymphoblastic leukemia (B-ALL) include Philadelphia chromosome-positive (Ph+) B-ALL driven by the BCR-ABL1 oncogene and a more recently identified subtype known as BCR-ABL-like or Ph-like B-ALL. A hallmark of both Ph+… read more here.
Keywords: enhances efficacy; mtor inhibition; dasatinib; inhibition enhances ... See more keywords